0000721371-24-000005.txt : 20240109 0000721371-24-000005.hdr.sgml : 20240109 20240109064804 ACCESSION NUMBER: 0000721371-24-000005 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240109 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240109 DATE AS OF CHANGE: 20240109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CARDINAL HEALTH INC CENTRAL INDEX KEY: 0000721371 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] ORGANIZATION NAME: 07 Trade & Services IRS NUMBER: 310958666 STATE OF INCORPORATION: OH FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11373 FILM NUMBER: 24521692 BUSINESS ADDRESS: STREET 1: 7000 CARDINAL PLACE CITY: DUBLIN STATE: OH ZIP: 43017 BUSINESS PHONE: 6147573033 MAIL ADDRESS: STREET 1: 7000 CARDINAL PLACE CITY: DUBLIN STATE: OH ZIP: 43017 FORMER COMPANY: FORMER CONFORMED NAME: CARDINAL DISTRIBUTION INC DATE OF NAME CHANGE: 19920703 8-K 1 cah-20240109.htm 8-K cah-20240109
0000721371false00007213712024-01-092024-01-09

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 9, 2024
 
Cardinal Health, Inc.
(Exact Name of Registrant as Specified in Charter)
 
Ohio 1-11373 31-0958666
(State or Other Jurisdiction
of Incorporation)
 (Commission
File Number)
 (IRS Employer
Identification No.)
7000 Cardinal Place, Dublin, Ohio 43017
(Address of Principal Executive Offices) (Zip Code)
(614) 757-5000
(Registrant’s telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common shares (without par value)CAHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨





Item 2.02.    Results of Operations and Financial Condition.

On January 9, 2024, Cardinal Health, Inc. (the “Company”) issued a news release announcing, among other things, progress on the Company’s ongoing business and portfolio review, including an updated enterprise operating and segment reporting structure, and an update to its fiscal year 2024 non-GAAP diluted earnings per share outlook. In the news release, the Company also provided an update to its previous expectations for Medical segment profit for the quarter ended December 31, 2023. A copy of this news release is included as Exhibit 99.1 to this report.

Item 7.01.    Regulation FD Disclosure.

The Company today will host a conference call beginning at 8:30 a.m. Eastern time during which management will discuss today's announcements. The event will be live-webcast and archived on the Company’s Investor Relations website. To access the webcast and corresponding slide presentation, visit ir.cardinalhealth.com. No access code is required.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.
99.1
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
2


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
  Cardinal Health, Inc.
(Registrant)
Date: January 9, 2024  By: /s/ Aaron E. Alt
   Name: Aaron E. Alt
   Title: Chief Financial Officer

3
EX-99.1 2 exhibit991-january92024pre.htm EX-99.1 Document
Exhibit 99.1

image_0a.jpg

Cardinal Health Announces Progress on Business and Portfolio Review and Fiscal 2024 Outlook Update


Progress achieved on company’s ongoing business and portfolio review
oCompleted review of growth businesses within the Medical Segment: investing in and further developing at-Home Solutions and OptiFreight® Logistics as part of the company’s portfolio for long-term growth and value creation
oReview of Global Medical Products and Distribution business continues, with focus on driving operational performance through the Medical Improvement Plan
oReorganizing leadership structure to continue company’s simplification efforts, prioritize core operational execution and drive efficiencies, accountability and transparency
Updated enterprise operating and segment reporting structure, effective January 1, 2024, to be reflected in company’s financial reporting beginning third quarter fiscal 2024
oProviding pro-forma long-term financial targets for updated segment reporting structure
Updated fiscal 2024 non-GAAP diluted EPS guidance to high end of $6.75 to $7.00 range
oPrimarily driven by favorability in Interest and Other and Diluted Weighted Average Shares Outstanding, enabled by continued strong cash flow generation and incremental share repurchase during second quarter fiscal 2024
oFurther updates and details to be provided on February 1 during fiscal 2024 Q2 earnings call

DUBLIN, Ohio – January 9, 2024 – Cardinal Health (NYSE:CAH) today announced progress on the company’s ongoing business and portfolio review, including an updated enterprise operating and segment reporting structure, and an update to its fiscal year 2024 non-GAAP diluted earnings per share (EPS) outlook. These updates build upon the company’s momentum, focus on long-term value creation, and continued actions to become more streamlined and focused. The company will host an analyst conference call today beginning at 8:30 a.m. E.T. where management will further discuss these announcements.
"We are excited to demonstrate further progress on how we are driving our company, and healthcare, forward” said Jason Hollar CEO of Cardinal Health. “As we continue down the path of becoming a simplified and more focused company, these actions align with our operational focus on the core of our business, provide increased visibility to key growth areas, and enable greater efficiencies across all our businesses. We continue to prioritize focused execution to best serve our customers and advance our mission as healthcare’s most trusted partner.”
Business and portfolio review update
While Cardinal Health’s business and portfolio review efforts remain active and ongoing, the company has completed a review of its growth businesses within the Medical Segment, at-Home Solutions and OptiFreight® Logistics, and has determined that investing in and further developing these businesses will drive the most significant long-term shareholder value creation for Cardinal Health. This conclusion follows the June 2023 announcement that the business review determined that Cardinal Health would retain and invest in its attractive Nuclear and Precision Health Solutions business.
Cardinal Health’s at-Home Solutions business, a $2.6B revenue leading home healthcare medical supplies provider serving people with chronic and serious health conditions in the United States, is well-positioned to continue to accelerate in the coming years with industry trends of care shifting to the home. To support increased demand, the company is investing in network expansion, and today, is announcing plans to build a new distribution center in Texas, with increased capacity, advanced automation and robotics within the facility. This is in addition to the recently opened site in Ohio, and the previously announced expansion in South Carolina set to open this calendar year.




Cardinal Health’s OptiFreight® Logistics, a $250M revenue leading provider of healthcare logistics, manages over 21 million shipments annually to 22,000 healthcare provider shipping locations across the continuum of care. Powered by its proprietary technology and team’s deep expertise, the business has a strong operational track record of profitable growth over many years. To sustain the business’ strong performance, the company continues to invest in innovative and technology-driven solutions such as TotalVue™ Insights that enable healthcare supply chain leaders to optimize their transportation and logistics processes and control shipping spend.
Cardinal Health’s review of its Global Medical Products and Distribution business continues, with a focus on executing the Medical Improvement Plan, which remains a critical priority for the enterprise. The company is continuing to drive ongoing initiatives and invest in the business to support customers’ needs and achieve its long-term target.
Operating and segment reporting structure update
The company also announced plans to realign its business to increase its focus on the core and accelerate its growth areas.
Effective January 1, 2024, the company began operating under an updated enterprise operating and segment reporting structure, which includes two reportable segments Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution (GMPD). Separate from these two segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight® Logistics will be reported as Other1.
The Pharmaceutical and Specialty Solutions Segment, previously in the Pharmaceutical Segment, continues under the leadership of Debbie Weitzman. The segment consists of the company’s largest and most significant businesses, its resilient Pharmaceutical Distribution business and its higher-growth Specialty business, including both downstream Specialty Distribution and upstream Manufacturer Services. Weitzman will continue to report directly to Jason Hollar.
The GMPD segment, previously in the Medical Segment, continues to be led by Steve Mason. The segment consists of the company’s U.S. and International Products and Distribution businesses, as well as its WaveMark business. Mason will report directly to Jason Hollar and continue to have a pivotal role in driving the success of the Medical Improvement Plan.
Other consists of at-Home Solutions and OptiFreight® Logistics from the former Medical Segment, and Nuclear and Precision Health Solutions from the former Pharmaceutical Segment. Each of these businesses will continue to operate independently and each of the business leaders, Rob Schlissberg, at-Home Solutions; Emily Gallo, OptiFreight® Logistics; and Mike Pintek, Nuclear and Precision Health Solutions, will now report directly to Jason Hollar. This updated operating structure is designed to provide greater visibility to the performance of these businesses and allow prioritization of investments to ensure their long-term success.
The company plans to report its second quarter fiscal 2024 results on February 1, 2024, according to its former reporting segments and will then report its third quarter fiscal 2024 results and forward on the basis of its updated structure.
Fiscal 24 outlook update
The company updated fiscal year 2024 non-GAAP diluted EPS guidance to the high end of its $6.75 to $7.00 range.
This update is driven by anticipated favorability in fiscal 24 Interest and Other and Diluted Weighted Average Shares Outstanding, due to continued strong cash flow generation, resulting in higher-than-expected cash balances, and the execution of a new $250M accelerated share repurchase program in the second quarter.
The company also provided an update to its previous expectations for second quarter Medical segment profit. While utilization trends, including Cardinal Health™ Brand volumes, and inflation mitigation efforts have trended according to the company’s expectations in the GMPD business, the company now anticipates second quarter Medical segment profit to be generally consistent with first quarter Medical segment profit, due to anticipated non-recurring adjustments in the second quarter. These anticipated non-recurring adjustments do not affect the company’s progression towards its previously-communicated fiscal 26 targets.
The company will provide further updates and details on its fiscal second quarter results and its fiscal 24 guidance during its second quarter earnings call, on February 1, 2024.




Long-term financial targets
The company reiterated its long-term financial targets reflecting 12% to 14% growth of non-GAAP diluted EPS2.
The company also provided pro-forma long-term targets for its updated segment reporting structure, and, for information purposes, recast its fiscal 2023 actuals on the same basis3.
The company’s previously announced Medical Improvement Plan targeting at least $650M of segment profit by fiscal 26 continues, with elements of that plan to reside in the results of both GMPD and Other.

FY23 Actuals3
Long-term TargetBusinesses
Pharmaceutical and Specialty Solutions
Revenue:
~$188.8B
Segment Profit:
~1.87B
4-6%
Segment Profit CAGR2
Former Pharmaceutical Segment, excluding Nuclear and Precision Health Solutions
GMPD
Revenue:
~$12.1B
Segment Profit:
~$(165)M
~$300 million
in Segment Profit by FY26
Former Medical Segment, excluding at-Home Solutions and OptiFreight® Logistics
Other
Revenue:
~$4.1B
Segment Profit:
~$410M
8-10%
Segment Profit CAGR2
at-Home Solutions, Nuclear and Precision Health Solutions and OptiFreight® Logistics

The company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably estimated. See “Forward-Looking Non-GAAP Measures” below for additional explanation.
Analyst Conference Call and Webcasted Investor Events
The company will hold an analyst conference call, which will be webcast, to discuss today’s announcements prior to the opening of trading on the New York Stock Exchange beginning at 8:30 a.m. Eastern.
Additionally, the company plans to present at the 42nd Annual J.P. Morgan Healthcare Conference today beginning at 5:15 p.m. Eastern.
To access the webcasts and corresponding presentations, visit Cardinal Health’s Investor Relations page. No access code is required. Presentation slides and a webcast replay will be available on the Investor Relations page for 12 months.
About Cardinal Health
Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With more than 50 years in business, operations in more than 30 countries and approximately 48,000 employees globally, Cardinal Health is essential to care. Information about Cardinal Health is available at cardinalhealth.com.
Contacts
Media: Erich Timmerman, erich.timmerman@cardinalhealth.com and 614.757.8231
Investors: Matt Sims, matt.sims@cardinalhealth.com and 614.553.3661
1 Other includes the following three operating segments: at-Home Solutions, Nuclear and Precision Health Solutions and OptiFreight® Logistics, which are not significant enough individually to require reportable segment disclosure.
2 FY24 to FY26 CAGR, as of FY23 baseline.



3 Recast FY23 actuals for updated segment reporting structure are considered preliminary and pending a final recast of segment results that is expected to be completed by the company’s Q3 FY24 earnings release. The sum of the components may reflect rounding adjustments.

Cautions Concerning Forward-Looking Statements
This news release contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," “will," "should," "could," "would," "project," "continue,” "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook, preliminary recast fiscal 2023 results and various accruals and estimates. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These risks and uncertainties include risks arising from ongoing inflationary pressures, including the risk that our plans to mitigate such effects may not be as successful as we anticipate or that costs could remain elevated; the possibility that our Medical unit goodwill could be further impaired due to additional changes to our long-term financial plan, increases in global interest rates or unfavorable changes in the U.S. statutory tax rate; risks associated with our ongoing review of our operations, portfolio and businesses, including the risk that our management team could become distracted or that the outcome of such review may have unintended consequences; competitive pressures in Cardinal Health's various lines of business, including the risk that customers may reduce purchases made under their contracts with us or terminate or not renew their contracts; the performance of our generics program, including the amount or rate of generic deflation and our ability to offset generic deflation and maintain other financial and strategic benefits through our generic sourcing venture or other components of our generics programs; ongoing risks associated with the distribution of opioids, including the financial impact associated with the settlements with governmental authorities and the risk that challenges to tax deductions for opioid-related losses could adversely impact our financial results; risks arising from the Department of Justice investigation which we believe concerns our anti-diversion program and risks associated with the injunctive relief requirements under the national settlement, including the risk that we may incur higher costs or operational challenges in the implementation and maintenance of the required changes; risks associated with the manufacture and sourcing of certain products, including risks related to our ability and the ability of third-party manufacturers to import or export certain products or component parts and to comply with applicable regulations; our ability to manage uncertainties associated with the pricing of branded pharmaceuticals; uncertainties related to the timing, magnitude and profit impact of the distribution of recently commercially available COVID-19 vaccines; risks associated with business process initiatives, such as the Medical Improvement Plan, including the possibility that they could fail to achieve the intended results; and the risk that we may not realize the anticipated benefits related to our updated operating and segment reporting structure. Cardinal Health is subject to additional risks and uncertainties described in Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports and exhibits to those reports. This news release reflects management’s views as of January 9, 2024. Except to the extent required by applicable law, Cardinal Health undertakes no obligation to update or revise any forward-looking statement. Forward-looking statements are aspirational and not guarantees or promises that goals, targets or projections will be met, and no assurance can be given that any commitment, expectation, initiative or plan in this news release can or will be achieved or completed.
Forward Looking Non-GAAP Measures
In this news release, the company presents certain forward-looking non-GAAP metrics. The company does not provide outlook on a GAAP basis because the items that the company excludes from GAAP to calculate the comparable non-GAAP measure can be dependent on future events that are less capable of being controlled or reliably predicted by management and are not part of the company’s routine operating activities. Additionally, management does not forecast many of the excluded items for internal use and therefore cannot create or rely on outlook done on a GAAP basis.
The occurrence, timing and amount of any of the items excluded from GAAP to calculate non-GAAP could significantly impact the company’s fiscal 2024 GAAP results. Over the past five fiscal years, the excluded items have impacted the company’s EPS from $0.75 to $18.06, which includes a $17.54 charge related to the opioid litigation the company recognized in fiscal 2020.
Definitions
Non-GAAP net earnings attributable to Cardinal Health, Inc.: net earnings attributable to Cardinal Health, Inc. excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) shareholder cooperation agreement costs, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, net, (7) litigation (recoveries)/charges, net and (8) loss on early extinguishment of debt.



Non-GAAP diluted earnings per share attributable to Cardinal Health, Inc.: non-GAAP net earnings attributable to Cardinal Health, Inc. divided by diluted weighted-average shares outstanding.

EX-101.SCH 3 cah-20240109.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 cah-20240109_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 5 cah-20240109_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 image_0a.jpg begin 644 image_0a.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# (! 0(! 0(" @(" @(" P4# P,# M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_ MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P, M# P,# P,# P,# P,# P,# P,# P,# S_P 1" !M 0<# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]V-1\=7^B MP![GPSK4HW8)LC#9QL,FK6LVFB,G@$2 M3HL9/T)%>@TRXMX[N%HY422-QAD< JP]"#64HS^R_O7^5COHUL+?]]3?_;LK M?^E*7Z'%:?)K'B.QCO\ POXUT;6+/9\IN+2.[BF..#YMN\>/J ?I7,^,?$'C M&Q2W;Q+\,;3Q7;V@9Q=^'-3CEN8">"4AN1"P)'79(Q/O5GQK^Q1\,O&NH/?_ M /",0:%J[9(U/P_/+HMZ&/\ $9;5HV8YY^8D5QNK?LZ_&GX7L9_AS\9'UZVC M(*Z+\0M-34HG '*B^M_*N4SZN)3]:XJKKQ6L6U_=:?X2M^%V?49>LKJMPZ5XY\2?VU=3\ :!-HO[2WP#U.R\-2?)MI6FWPUGP\6Z[9M,N&)MR2<'RS M$1GI7!'%RE+DI2O+LO=E_P" 3T?KIY'U=7A^C2H*OC:7)2>BJ22KT&_/$8:U M2+_NVJ/^8]O^''[=7PX^(/BY/#-SJUSX1\8/P/#WBBT?1]2O8*^%?C=^T9J'@OPX?"G[87P7TG6/!DCB-/&_AVT?5M!5CP)986!N;%^,[ MADY/RGC-:O@KP)\0/@IX,M?&?[-7C^W^-/PPD7S1X)U_5A>.D0&3'INIDEXW M'00W!91TR#Q6M'-9\SC)L'JUYQ;OT1P9CP%AW2C6HS]CSZ0E*4:F M'J/M'$PM&$O[E6,>5?'-,^U:*\G_ &5OVR/"?[6.B7_]D?;]&\3:!(+?7O#. MKP_9M6T*?^Y-$>=I.=KKE6['.0.[^(?Q0\-?"/P[)J_BKQ!HWAS2X?OW>IWD M=K"/;A_MN:7\4FQ\-O"?C+X@POD)J=KIYT_1R0\(D_'BK MOB_XRZQX!THZAX[\2?#CX96$T8\M;K4#=SAL] \A@0GV5&_&LUC:37-%W7?I M]^WXG9+AK,(5%1K0Y)O[+^/_ ,%J]3_R4]?HKQ_P5^U%IOBNV3_A&-/\<_$% M9B,7]MHOV.Q/;*3W @B9?=6?KWKM+'7/&&JVKR2:)HVAA6X^U:@UR^WU*QH% M'_?9JX8B$U>&OIK^.WXG+B5V[@1J2WZ5K:#XQL?$TSI9F[<(N_S'LYHHV'^R[J% M8^P)K15(-V3.2>#KPCSS@TN[3L:E%%%6KZBHKFQ.$HXB/)6BI+\O1 M[I^:/9R3B+,LGK_6CL])+M*/PRB^L9)I]4?GAKW[8/[0'_!.4_P!E M_M">%8?B]\+)?]%_X3CP_:K]H@B8!?\ 3+<@(>.H8+G)P\AXK-U7X1^"M+\" MZM^T9^R!\4_#O@:&RC-_XBT&\N?*\,ZBH7@X49(V[,[J_1O4- M/M]6L)K6Z@AN;6Y1HIH94#QRH1@JRG@@C@@U^2G_ 5I_P"">?@S]C35-)^* MGPKU/3/#^K:KK-J$^'EU;&^L?$URDRL@M[0!MX5B&:)E,8_A*':K?+YOA*^$ MHNK?VE..JN[3AYQGNUY/5[7>Q^]>'?$.5Y_F4,!R_4L76:C)4X<^%Q*W<*V' M=XTVUM4@N2+][EA;F)O#_P"T]XM_X*B_&?2-<^&FD^%?@+\5/ FA?;M6\4:O MJ16^U"VDB;-O%;; +BR)\MR\X81AD(P<;^H\$?%+X.^'_&UBGA;P9XS_ &M_ MC^L$ 5G=OW\Z-(&C,2;G0L3M4: M\'"8SVE2\I9<_)4Q#,;FT/ MP=/%;W008_=R:I+?VH?BCJ7QM^)H0 M2K8:M,UZ48@?+#IRLP5.F#.VSCC;76^$OVP?VE_VQ=,MM.^ 'PBTGX0> HC MM?$WBZ(1E8L\-;VJKLQUX5)5]Q7KNO:KRS?O]E^]J_\ R%/[K'YY#+%4P+K8 M97PKT=27^PX)^22MB<5ZN2J>3/;5\-_M(_$;3I-2\J0D>AKR7Q5\>OV5_ 'B)--UWQ]XP^/GBY6*I81ZA>^*9 M974\JMM;8LU^;ML49KH/"?\ P1ILOB1J,&L_M ?$[QQ\:M64K(;"YOI+#186 M!SA+>)LXSZ,H(_AKZL^$GP%\$_ 70ETSP7X4T#PO8JNTQZ;8QV^_G/S%0"QS MW8DUZM+"8NKK**C_ (VYO_P%-07R;/@3[EYXPU&T\-QI[FSMTFG(_P" MK^%=_H_@3X_>+$C?Q#X_\ ^$Q_';^&O#DMZ_T\^\F*GZ^2/I7MU%>I3P32M4 MJ2?W17_DJ7XMGP6,XHA.3EA,)2IWZM2JR?JZTJBOYQC'T//-.^!.H,8I-7^( M7CK5YT^_MN;>QB<_[EM#'@?C77Z1X1M=%F62*74970$ W%_/..?9W(_2M2BN MN%*$=E^OYG@8C,*];2PZ'>OIL5O M-J*P.;6.=RD4DNT[ [ $A2V,D D#/%?GS\5?BIX/_P""1/AF]\3>(3'\5?VI M/BLQFE\I&::YED.U8HE +P6$;;8T11OEV O+Z+K)W M]WMOO9/]1\+<'[?'3ITX2KU)KDC0@^5U;ZOVE33V="*C>JTTY*T;J+E*/R]^ MW;_P39\7?#GX.ZG^T-\9/B7X03XQ7VIP:E_PCL]K --O50+_ *$B@8GF "_* M%*%5(8MGS*]4^%G[8W[3/_!6#PW:^&O@QHVB?!?P%I4$6GZ[XC@E^:*<1(9( MK<@!HQ\V5CB7<%*[I%!KT+]EW_@E/XO_ &I_B)!\9?VM+^;Q'K]R!-I?@QFV MV.DQD[E29%.T 1422&$8 2>&1RVTJ33L];6/VSB3Q+RBE@7E^+G1QN882,I49^S2PE)WA%T*,$TJG)"+= M.=2+BY1M%2YD"BO+]>_JS^7N(.)&%%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% 'E_P"V1^T_I7['G[.OB+QYJL1N MSI<(CL;)#^\U&\D.R"W7'.6/]6OR#G<6^H?C%^SKH'QT\6>"-3\0_:+N M#P)JQURRT\E?LMQ>")HX995(RQBWLZ $ -@G.!72?$/X@Z+\)_ FL>)_$FI6 MNCZ!H%G+?ZA?7+[8K6"-2SNQ] >G)[5YE3 ^WQ2K5]8P^%=+]9/S6R[:OJ? MIM+V:?NT8O=1E;GJ-?'>,7I%WV:*_%;QC_P'=A9Y(XY(XK5&["21F/L3+<0Q& ,9986.V0MA M6##;T(Z>F?#'W_1110 4444 %%?'W_!>/XU>+?V>_P#@E]\0O%G@;Q#J?A7Q M-ILNG"UU+3Y!'<6X>_@1]I(.,HS*?8FO%_V"?C=^T'^T/_P;^KXL\%^(M2\5 M_'K4$U!-'U+4I+>2>>:/570!C.!$=L"LHW\8 [T ?I317S-_P2>/[0Q_96?_ M (::VCXE?VW=;=OV/'V'$?D_\>O[OKYG^UZ]J^F: "BBB@ HHK\WFNMLL1)!^5UX( MH ^TJ*** "BBB@ HKXX^%OQM\7ZO_P %S/BIX NO$6J3^"=(^%^DZM9:*\@- MI:WE>^_#O]J[PC\4OVB_B#\+M(EU"3Q5\,H-/GUQ9+1H[ M>(7L;2P".0\2'8I)P,#(&E45\9?!;XX>,-=_X+D_&KP#>>(]4N?!.A?# MO1=2T_17D!M+.ZEEQ),BXX=AP3FOLV@ HHHH **** "BBB@ HHHH *_-C_@Z ME^+>H?#O_@F =&T^66!/&_BBPTB]9&V[[=1+=,A]0S6Z CN,U^D]?%O_ 7X M_8UUG]M;_@FUXJT3PQ9/J7BKPO

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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Cover Page
Jan. 09, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jan. 09, 2024
Entity Registrant Name Cardinal Health, Inc.
Entity Incorporation, State or Country Code OH
Entity File Number 1-11373
Entity Tax Identification Number 31-0958666
Entity Address, Address Line One 7000 Cardinal Place
Entity Address, City or Town Dublin
Entity Address, State or Province OH
Entity Address, Postal Zip Code 43017
City Area Code 614
Local Phone Number 757-5000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common shares (without par value)
Trading Symbol CAH
Security Exchange Name NYSE
Entity Emerging Growth Company false
Entity Central Index Key 0000721371
Amendment Flag false

XML 8 cah-20240109_htm.xml IDEA: XBRL DOCUMENT 0000721371 2024-01-09 2024-01-09 0000721371 false 8-K 2024-01-09 Cardinal Health, Inc. OH 1-11373 31-0958666 7000 Cardinal Place Dublin OH 43017 614 757-5000 false false false false Common shares (without par value) CAH NYSE false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.cardinal.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports cah-20240109.htm cah-20240109.xsd cah-20240109_lab.xml cah-20240109_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "cah-20240109.htm": { "nsprefix": "cah", "nsuri": "http://www.cardinal.com/20240109", "dts": { "inline": { "local": [ "cah-20240109.htm" ] }, "schema": { "local": [ "cah-20240109.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "cah-20240109_lab.xml" ] }, "presentationLink": { "local": [ "cah-20240109_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.cardinal.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240109.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "cah-20240109.htm", "first": true, "unique": true } } }, "tag": { "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.cardinal.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0000721371-24-000005-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000721371-24-000005-xbrl.zip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end